ACE-031 1mg 1mg*10vials

Description

ACE-031 Myostatin Inhibitor Decoy Receptor Research

Mode of Action

The biochemical activity of ACE-031 is defined by its role as a ligand trap within the TGF-beta superfamily signaling pathway. Initially, the soluble ACVR2B-Fc fusion protein competitively binds to GDF-8 (myostatin) and GDF-11, preventing these inhibitory growth factors from activating the cell-bound ACVR2B receptor. This defines the first semantic triple: [ACE-031 sequesters myostatin]. Additionally, this ligand sequestration effectively inhibits the downstream phosphorylation of SMAD2/3 proteins. This establishes the second triple: [ACVR2B-Fc blockade dampens SMAD signaling]. Thirdly, the reduction in SMAD signaling releases the inhibition on myogenic regulatory factors, thereby promoting myoblast differentiation and hypertrophy. This forms the third triple: [Myostatin inhibition facilitates myogenesis]. Quantitatively, ACE-031 demonstrates a systemic half-life of approximately 12.5 +/- 2 days in primate models. Unlike Follistantin, which binds a broader range of ligands including BMPs, ACE-031 is more specifically tuned to the activin receptor ligands.

About This Compound

ACE-031 is a recombinant fusion protein consisting of the extracellular domain of the activin receptor type IIB (ACVR2B) linked to the Fc portion of human IgG1. This signaling molecule functions as a potent decoy receptor that sequesters ligands such as myostatin and activins before they can engage endogenous cell-surface receptors. [ACE-031 binds GDF-8].

Product Specifications

• CAS Number: 1160514-60-2
• Molecular Formula: C3818H5856N1024O1162S30 (Approximate)
• Molecular Weight: ~110-120 kDa (Glycosylated Dimer)
• Purity: >99.0% via HPLC-UV and SEC-HPLC
• Appearance: Fine white sterile lyophilizate

Research Observations

• Enhanced Lean Mass Accumulation: Investigators observe significant increases in muscle thickness and density within short research windows.
• Increased Grip Strength: Study data demonstrates measurable improvements in isometric force production across various research models.
• Modulation of Adipose Tissue: As documented in protocols, research shows a secondary effect of reduced fat mass, likely linked to the increased metabolic demand of new muscle tissue.
• Bone Mineral Density Support: Multiple research groups note that myostatin inhibition may have positive cross-talk effects on osteoblast activity.
• Improved Insulin Sensitivity: Research models demonstrate localized improvements in glucose disposal rates within skeletal muscle.

In Brief:
ACE-031 represents a high-feasibility research tool for investigating the profound effects of myostatin sequestration on musculoskeletal homeostasis.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.